{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:19:25Z","timestamp":1772633965284,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41375-025-02847-5","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:19:51Z","timestamp":1768810791000},"page":"553-561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5379-7461","authenticated-orcid":false,"given":"Delphine","family":"Rea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slawomira","family":"Kyrcz-Krzemien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Sportoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-9887","authenticated-orcid":false,"given":"Ji\u0159\u00ed","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpad","family":"Illes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Angona Figueras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2494-4087","authenticated-orcid":false,"given":"Alexander","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0986-9530","authenticated-orcid":false,"given":"Aude","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros","family":"Marinakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Stenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-5355","authenticated-orcid":false,"given":"Juan Luis","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-3514","authenticated-orcid":false,"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4737-1103","authenticated-orcid":false,"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schuld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2847_CR1","unstructured":"Tasigna (Nilotinib) Prescribing Information. 2024. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/tasigna.pdf."},{"key":"2847_CR2","unstructured":"Tasigna (Nilotinib) Summary of Product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tasigna-epar-product-information_en.pdf."},{"key":"2847_CR3","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"2847_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"2847_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2847_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2024;22:43\u201369.","journal-title":"J Natl Compr Cancer Netw"},{"key":"2847_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"2847_CR8","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1038\/leu.2017.247","volume":"31","author":"TP Hughes","year":"2017","unstructured":"Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, et al. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 2017;31:2529\u201331.","journal-title":"Leukemia"},{"key":"2847_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11899-024-00728-9","volume":"19","author":"D Rea","year":"2024","unstructured":"Rea D, Fodil S, Lengline E, Raffoux E, Cayuela J-M. Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: strategies to optimize success and new directions. Curr Hematol Malig Rep. 2024;19:104\u201310.","journal-title":"Curr Hematol Malig Rep"},{"key":"2847_CR10","doi-asserted-by":"crossref","unstructured":"Chen K-k, Du T-f, Xiong P-s, Fan G-h, Yang W. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis. Front Oncol. 2019;9:372.","DOI":"10.3389\/fonc.2019.00372"},{"key":"2847_CR11","doi-asserted-by":"publisher","first-page":"ix95","DOI":"10.1093\/annonc\/mdz427.016","volume":"30","author":"J Cho","year":"2019","unstructured":"Cho J, Kim J, Park J, Lim JH, Lee MH. Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: a systematic review and meta-analysis. Ann Oncol. 2019;30:ix95\u20136.","journal-title":"Ann Oncol"},{"key":"2847_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"2847_CR13","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375\u201383.","journal-title":"Lancet Haematol"},{"key":"2847_CR14","doi-asserted-by":"crossref","unstructured":"Hughes TP, Yong AS, Ross DM. The evolution of treatment-free remission. Blood. 2025;blood.2024026310.","DOI":"10.1182\/blood.2024026310"},{"key":"2847_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"NP Shah","year":"2020","unstructured":"Shah NP, Garcia-Gutierrez V, Jimenez-Velasco A, Larson S, Saussele S, Rea D, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61:650\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2847_CR16","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.23.01647","volume":"42","author":"FX Mahon","year":"2024","unstructured":"Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission. J Clin Oncol. 2024;42:1875\u201380.","journal-title":"J Clin Oncol"},{"key":"2847_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M17-1094","volume":"168","author":"FX Mahon","year":"2018","unstructured":"Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168:461\u201370.","journal-title":"Ann Intern Med"},{"key":"2847_CR18","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","volume":"35","author":"TP Hughes","year":"2021","unstructured":"Hughes TP, Clementino NCD, Fominykh M, Lipton JH, Turkina AG, Moiraghi EB, et al. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia. 2021;35:1631\u201342.","journal-title":"Leukemia"},{"key":"2847_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/ejh.70006","volume":"115","author":"A Lagana","year":"2025","unstructured":"Lagana A, Scalzulli E, Carmosino I, Bisegna ML, Ielo C, Diverio D, et al. Treatment Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML): analysis of predictive factors and novel baseline scoring system to predict molecular relapse. Eur J Haematol. 2025;115:367\u201379.","journal-title":"Eur J Haematol"},{"key":"2847_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846\u201354.","journal-title":"Blood"},{"key":"2847_CR21","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","volume":"7","author":"S Kimura","year":"2020","unstructured":"Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7:e218\u20135.","journal-title":"Lancet Haematol"},{"key":"2847_CR22","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gomez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525\u201331.","journal-title":"Leukemia"},{"key":"2847_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.769730","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zou J, Cheng F, Li W. Treatment-free remission in chronic myeloid leukemia and new approaches by targeting leukemia stem cells. Front Oncol. 2021;11:769730.","journal-title":"Front Oncol"},{"key":"2847_CR24","doi-asserted-by":"crossref","unstructured":"Mojtahedi H, Yazdanpanah N, Rezaei N. Chronic myeloid leukemia stem cells: targeting therapeutic implications. Stem Cell Res Ther. 2021;12:603.","DOI":"10.1186\/s13287-021-02659-1"},{"key":"2847_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","volume":"144","author":"DM Ross","year":"2018","unstructured":"Ross DM, Masszi T, G\u00f3mez Casares MT, Hellmann A, Stentoft J, Conneally E, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018;144:945\u201354.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2847_CR26","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841\u201351.","journal-title":"Lancet Oncol"},{"key":"2847_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"SE Lee","year":"2016","unstructured":"Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101:717\u201323.","journal-title":"Haematologica"},{"key":"2847_CR28","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","volume":"32","author":"J Richter","year":"2014","unstructured":"Richter J, S\u00f6derlund S, L\u00fcbking A, Dreimane A, Lotfi K, Markev\u00e4rn B, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?. J Clin Oncol. 2014;32:2821\u20133.","journal-title":"J Clin Oncol"},{"key":"2847_CR29","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Sau\u00dfele","year":"2016","unstructured":"Sau\u00dfele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638\u201347.","journal-title":"Leukemia"},{"key":"2847_CR30","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440\u201353.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02847-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02847-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02847-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:38:25Z","timestamp":1772609905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02847-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2847"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02847-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DR is on the advisory board for Novartis, Enliven, TERNS, and Ascentage Pharma and is a consultant for TERNS and Novartis. JM received research support from Novartis. AI received consulting fees from Janssen, Swixx, Takeda, Astrazeneca, Astellas, Eli Lilly, Roche; honoraria from Astrazeneca, Astellas, Eli Lilly, Roche, Sobi; travel\/meeting support from AbbVie, Sobi; Is on data monitoring\/ advisory board at Sobi, Bristol-Myers Squibb, Johnson & Johnson, Novartis, AbbVie, Astellas, Roche, Astrazeneca. AK declared Novartis honoraria membership on an entity\u2019s board of directors or advisory committees, research funding, and speakers bureau. AC has served on advisory boards and has acted as a speaker for Bristol-Myers Squibb, Incyte, Novartis, and Pfizer. PS declared that he is an employee of Novartis. LS received consulting fees from Xspray Pharma Sweden. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}